Emergent BioSolutions stock reaffirms buy rating on contract modification
H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
Emergent BioSolutions’ Growth Potential: Ebola Vaccine Contract, Naloxone Expansion, and Monkeypox Study Drive Buy Rating
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions (EBS – Research Report), with a ...
Emergent BioSolutions: Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC's support for the MOSA, a pan-African randomized platform ad ...
Emergent BioSolutions starts enrollment in Africa or cDC-led MPox study
Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has ...
FiercePharma6d
JPM25: Emergent secures licensing deal for opioid overdose spray amid recovery plan
After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it ...
FiercePharma6d
JPM25, Day 3: AbbVie's 'clear runway to growth' allows it to focus on early-stage acquisitions
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...